ifosfamide has been researched along with Alopecia Cicatrisata in 32 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Doxorubicin and ifosfamide are highly active drugs for the treatment of high-grade sarcomas, but little is known on the optimal management of young patients who develop such malignancies during pregnancy." | 9.16 | Doxorubicin and ifosfamide for high-grade sarcoma during pregnancy. ( Berrada, N; Bonvalot, S; Boulet, B; Cioffi, A; Domont, J; Le Cesne, A; Lokiec, F; Mir, O; Terrier, P; Trichot, C, 2012) |
| "The efficacy and feasibility of a novel sequential schedule of high-dose ifosfamide (HD-IFO) and full-dose epirubicin (EPI) with granulocyte colony-stimulating factor (G-CSF) was evaluated in adult patients with soft tissue sarcomas (STS)." | 9.09 | A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule. ( Cognetti, F; Gamucci, T; Nardi, M; Serrone, L; Zeuli, M, 2001) |
| "This Phase II trial of paclitaxel/ifosfamide included patients with bi-dimensionally measurable metastatic breast cancer in second or third relapse, following anthracycline-containing regimens; ECOG PS < 2, and adequate hepatic, cardiac, renal, and hematological functions." | 9.08 | Phase II trial of paclitaxel and ifosfamide as a salvage treatment in metastatic breast cancer. ( Amorim, WC; Ferreira-Filho, AF; Guimaraes, RC; Morici, AC; Murad, AM; Schwartsmann, G, 1997) |
| "A phase II study of high-dose ifosfamide in hepatocellular carcinoma was conducted among 17 Chinese patients." | 9.07 | Phase II study of high-dose ifosfamide in hepatocellular carcinoma. ( Lau, WY; Leung, N; Leung, WT; Li, AK; Lin, J; Shiu, W; Tao, M, 1993) |
| "Early results with ifosfamide plus mesna in soft tissue sarcoma showed an initial response rate of 38% in 42 patients." | 7.67 | Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma. ( Fisher, C; Harmer, C; McKinna, A; Westbury, G; Wiltshaw, E, 1986) |
| "In a prospective study, 18 evaluable patients with recurrent osteosarcoma were treated with ifosfamide, 1." | 7.67 | High-dose ifosfamide in advanced osteosarcoma. ( Berchtold, W; Cserhati, M; Kroner, T; Marti, C; Remagen, W; Varini, M, 1985) |
| " Mesna was administered intravenously at a 20% of the ifosfamide dosage before ifosfamide and orally at 40% after 4 and 8 hours from the ifosfamide infusion." | 6.68 | Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer. ( Pensa, F; Pronzato, P; Tani, F; Vaira, F; Vanoli, M; Vigani, A, 1997) |
| "Doxorubicin and ifosfamide are highly active drugs for the treatment of high-grade sarcomas, but little is known on the optimal management of young patients who develop such malignancies during pregnancy." | 5.16 | Doxorubicin and ifosfamide for high-grade sarcoma during pregnancy. ( Berrada, N; Bonvalot, S; Boulet, B; Cioffi, A; Domont, J; Le Cesne, A; Lokiec, F; Mir, O; Terrier, P; Trichot, C, 2012) |
| "The MSC cold cap system is effective in preventing alopecia from anthracycline, etoposide or taxane but not from anthracycline-taxane combinations or ifosfamide-containing regimens." | 5.10 | Effectiveness of the MSC cold cap system in the prevention of chemotherapy-induced alopecia. ( Christodoulou, C; Efstathiou, E; Klouvas, G; Papazachariou, E; Plyta, M; Skarlos, DV; Zervakis, D, 2002) |
| "The efficacy and feasibility of a novel sequential schedule of high-dose ifosfamide (HD-IFO) and full-dose epirubicin (EPI) with granulocyte colony-stimulating factor (G-CSF) was evaluated in adult patients with soft tissue sarcomas (STS)." | 5.09 | A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule. ( Cognetti, F; Gamucci, T; Nardi, M; Serrone, L; Zeuli, M, 2001) |
| "This two-arm, double-blind, randomized trial was conducted to determine the effects of lenograstim, a glycosylated recombinant human granulocyte colony-stimulating factor (rHu-G-CSF), on the hematologic tolerance of patients with sarcoma treated with mesna, doxorubicin, ifosfamide, and doxorubicin (MAID) chemotherapy." | 5.08 | Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. ( Bonichon, F; Bui, BN; Chevallier, B; Chevreau, C; Cupissol, D; Fargeot, P; Krakowski, I; Maugard-Louboutin, C; Peny, AM; Thyss, A, 1995) |
| "This Phase II trial of paclitaxel/ifosfamide included patients with bi-dimensionally measurable metastatic breast cancer in second or third relapse, following anthracycline-containing regimens; ECOG PS < 2, and adequate hepatic, cardiac, renal, and hematological functions." | 5.08 | Phase II trial of paclitaxel and ifosfamide as a salvage treatment in metastatic breast cancer. ( Amorim, WC; Ferreira-Filho, AF; Guimaraes, RC; Morici, AC; Murad, AM; Schwartsmann, G, 1997) |
| "We have reported the results of a previous Phase II trial of two courses of neoadjuvant mitomycin (6 mg/m2), ifosfamide (3 g/m2) and cisplatin (50 mg/m2) (MIC) in squamous or anaplastic carcinoma of the oesophagus." | 5.08 | A phase II trial of four courses of preoperative chemotherapy in squamous or anaplastic carcinoma of the oesophagus. ( Cullen, MH; Darnton, SJ; Matthews, HR; McAleer, JA; McManus, KG; Steyn, RS, 1998) |
| "A phase II study of high-dose ifosfamide in hepatocellular carcinoma was conducted among 17 Chinese patients." | 5.07 | Phase II study of high-dose ifosfamide in hepatocellular carcinoma. ( Lau, WY; Leung, N; Leung, WT; Li, AK; Lin, J; Shiu, W; Tao, M, 1993) |
| "Early results with ifosfamide plus mesna in soft tissue sarcoma showed an initial response rate of 38% in 42 patients." | 3.67 | Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma. ( Fisher, C; Harmer, C; McKinna, A; Westbury, G; Wiltshaw, E, 1986) |
| "In a prospective study, 18 evaluable patients with recurrent osteosarcoma were treated with ifosfamide, 1." | 3.67 | High-dose ifosfamide in advanced osteosarcoma. ( Berchtold, W; Cserhati, M; Kroner, T; Marti, C; Remagen, W; Varini, M, 1985) |
| "Grade 3-4 neutropenia was the dose limiting toxicity, observed in 36% of patients." | 2.71 | Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial. ( Brunetti, C; Cassano, G; Colucci, G; Galetta, D; Gebbia, V; Germano, D; Giampaglia, M; Guida, M; Izzi, G; Lorusso, V; Nettis, G; Silvestris, N; Spada, M, 2005) |
| "Neutropenia was the dose limiting toxicity (G1=6%, G2=11%, G3=10%, G4=7%)." | 2.70 | Vinorelbine, ifosfamide and cisplatin as first-line treatment in patients with inoperable non-small cell lung cancer. ( Camps, C; García, R; Maestu, I; Montalar, J; Morales, S; Segura, A; Torregrosa, D; Vadell, C; Yuste, AL, 2001) |
| " Our trial failed to demonstrate a significant improvement in response or survival when patients with metastatic NSCLC were treated, in addition to ifosfamide and mitomycin, by combination of moderate dosages of cisplatin and carboplatin instead of moderate dosage of cisplatin alone." | 2.69 | Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer. ( Alexopoulos, CG; Baumöhl, J; Berghmans, T; Florin, MC; Klastersky, J; Koumakis, G; Lafitte, JJ; Mommen, P; Ninane, V; Paesmans, M; Schmerber, J; Sculier, JP; Thiriaux, J; Zacharias, C, 2000) |
| "The prognosis of advanced ovarian cancer is very poor, with about 15% of patients surviving at five years." | 2.68 | Ifosfamide seven-day infusion for recurrent and cisplatin refractory ovarian cancer. ( Beuzeboc, P; Dorval, T; Garcia-Giralt, E; Jouve, M; Livartowski, A; Mosseri, V; Palangié, T; Pouillart, P; Sastre, X; Scholl, S; Soussain, C, 1996) |
| " Mesna was administered intravenously at a 20% of the ifosfamide dosage before ifosfamide and orally at 40% after 4 and 8 hours from the ifosfamide infusion." | 2.68 | Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer. ( Pensa, F; Pronzato, P; Tani, F; Vaira, F; Vanoli, M; Vigani, A, 1997) |
| "Ifosfamide was given every 3 weeks in a dose of 5 gm m-2 as a 24 h infusion with mesna, 1 gm m-2 by i." | 2.67 | A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma. The London Gynaecologic Oncology Group. ( Blake, PR; Fryatt, IJ; Gore, M; Harper, P; Perren, TJ; Slevin, M; Stein, R; Tan, S; Wiltshaw, E, 1993) |
| "A total of 37 men with epidermoid head and neck cancer whose disease had recurred following primary treatment (surgery and/or radiotherapy) received first-line chemotherapy with ifosfamide at i." | 2.67 | Ifosfamide in advanced epidermoid head and neck cancer. ( Almenarez, J; Casado, A; Diaz-Rubio, E; Dominguez, S; González Larriba, JL; López-Vega, JM; Martín, M; Sastre, J, 1993) |
| "Patients with hormone-unresponsive prostate cancer were scheduled to receive CDDP 70 mg/m2 intravenously on day 1 and IFM 1." | 2.40 | [Combination chemotherapy with cis-platinum and ifosfamide for hormone unresponsive prostate cancer]. ( Asahi, T; Hata, K; Katayama, Y; Kobashi, K; Kobuke, M; Kondo, K; Kumon, H; Maki, Y; Nanba, K; Nasu, Y; Ochi, J; Ohashi, T; Ohmori, H; Ozaki, Y; Saegusa, M; Saika, T; Tanahashi, T; Tsushima, T; Uno, S; Yamashita, Y, 1998) |
| "Paclitaxel was given at a dose of 120 mg/m2 to five patients, 135 mg/m2 to five patients, 150 mg/m2 to three patients, and 175 mg/m2 to 11 patients." | 1.29 | Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study. ( Asbury, RF; Boros, L; Chang, AY; Garrow, GC; Hui, L, 1996) |
| "The course of 72 patients (36 with squamous carcinoma, 25 with adenocarcinoma, two with alveolar-cell carcinoma and nine with large-cell carcinoma) could be evaluated." | 1.27 | [Chemotherapy of the non-small cell carcinoma of the lung with ifosfamide and cisplatin]. ( Abel, U; Dirks, HP; Drings, P; Grimm, V; Heinrich, S; Kleckow, M; Manke, HG; Queisser, W; Stiefel, P, 1984) |
| "Ifosfamide was studied in advanced pancreatic tumor at the National Cancer Institute, Cairo." | 1.27 | Ifosfamide in advanced pancreatic cancer. A 5-year experience. ( Gad-el-Mawla, N, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (25.00) | 18.7374 |
| 1990's | 15 (46.88) | 18.2507 |
| 2000's | 7 (21.88) | 29.6817 |
| 2010's | 2 (6.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mir, O | 1 |
| Berrada, N | 1 |
| Domont, J | 1 |
| Cioffi, A | 1 |
| Boulet, B | 1 |
| Terrier, P | 1 |
| Bonvalot, S | 1 |
| Trichot, C | 1 |
| Lokiec, F | 1 |
| Le Cesne, A | 1 |
| Luo, J | 1 |
| Wu, FY | 1 |
| Li, AW | 1 |
| Zheng, D | 1 |
| Liu, JM | 1 |
| Huang, YH | 1 |
| Wen, XP | 1 |
| Hu, L | 1 |
| Lorusso, V | 1 |
| Gebbia, V | 1 |
| Spada, M | 1 |
| Guida, M | 1 |
| Cassano, G | 1 |
| Brunetti, C | 1 |
| Germano, D | 1 |
| Nettis, G | 1 |
| Izzi, G | 1 |
| Galetta, D | 1 |
| Giampaglia, M | 1 |
| Silvestris, N | 1 |
| Colucci, G | 1 |
| Bo, LJ | 1 |
| Liang, AB | 1 |
| Liu, B | 1 |
| Chen, YH | 1 |
| Wang, F | 1 |
| Jin, XP | 1 |
| Drings, P | 1 |
| Stiefel, P | 1 |
| Dirks, HP | 1 |
| Grimm, V | 1 |
| Kleckow, M | 1 |
| Manke, HG | 1 |
| Queisser, W | 1 |
| Abel, U | 1 |
| Heinrich, S | 1 |
| Hartlapp, JH | 1 |
| Jaeger, N | 1 |
| Fischer, P | 1 |
| Weissbach, L | 1 |
| Morgan, LR | 1 |
| Harrison, EF | 1 |
| Hawke, JE | 1 |
| Hunter, HL | 1 |
| Costanzi, JJ | 1 |
| Plotkin, D | 1 |
| Tucker, WG | 1 |
| Worrall, PM | 1 |
| Bui, BN | 1 |
| Chevallier, B | 1 |
| Chevreau, C | 1 |
| Krakowski, I | 1 |
| Peny, AM | 1 |
| Thyss, A | 1 |
| Maugard-Louboutin, C | 1 |
| Cupissol, D | 1 |
| Fargeot, P | 1 |
| Bonichon, F | 1 |
| Perren, TJ | 1 |
| Wiltshaw, E | 2 |
| Harper, P | 1 |
| Slevin, M | 1 |
| Stein, R | 1 |
| Tan, S | 1 |
| Gore, M | 1 |
| Fryatt, IJ | 1 |
| Blake, PR | 1 |
| Lin, J | 1 |
| Shiu, W | 1 |
| Leung, WT | 1 |
| Tao, M | 1 |
| Leung, N | 1 |
| Lau, WY | 1 |
| Li, AK | 1 |
| Martín, M | 1 |
| Diaz-Rubio, E | 1 |
| González Larriba, JL | 1 |
| Casado, A | 1 |
| Sastre, J | 1 |
| López-Vega, JM | 1 |
| Almenarez, J | 1 |
| Dominguez, S | 1 |
| Chang, AY | 1 |
| Boros, L | 1 |
| Garrow, GC | 1 |
| Asbury, RF | 1 |
| Hui, L | 1 |
| Dorval, T | 1 |
| Soussain, C | 1 |
| Beuzeboc, P | 1 |
| Garcia-Giralt, E | 1 |
| Jouve, M | 1 |
| Livartowski, A | 1 |
| Mosseri, V | 1 |
| Palangié, T | 1 |
| Scholl, S | 1 |
| Sastre, X | 1 |
| Pouillart, P | 1 |
| Murad, AM | 1 |
| Guimaraes, RC | 1 |
| Amorim, WC | 1 |
| Morici, AC | 1 |
| Ferreira-Filho, AF | 1 |
| Schwartsmann, G | 1 |
| Pronzato, P | 1 |
| Vigani, A | 1 |
| Pensa, F | 1 |
| Vanoli, M | 1 |
| Tani, F | 1 |
| Vaira, F | 1 |
| Steyn, RS | 1 |
| Darnton, SJ | 1 |
| McManus, KG | 1 |
| McAleer, JA | 1 |
| Cullen, MH | 2 |
| Matthews, HR | 1 |
| Maki, Y | 1 |
| Tsushima, T | 2 |
| Nasu, Y | 2 |
| Kumon, H | 1 |
| Ohmori, H | 2 |
| Tanahashi, T | 1 |
| Nanba, K | 1 |
| Ohashi, T | 1 |
| Kondo, K | 1 |
| Saika, T | 1 |
| Asahi, T | 2 |
| Saegusa, M | 1 |
| Ozaki, Y | 2 |
| Yamashita, Y | 1 |
| Katayama, Y | 1 |
| Kobuke, M | 1 |
| Uno, S | 1 |
| Ochi, J | 1 |
| Kobashi, K | 1 |
| Hata, K | 1 |
| Han, JY | 1 |
| Kim, HK | 1 |
| Choi, BG | 1 |
| Moon, H | 1 |
| Hong, YS | 1 |
| Lee, KS | 1 |
| Sculier, JP | 1 |
| Lafitte, JJ | 1 |
| Paesmans, M | 1 |
| Thiriaux, J | 1 |
| Alexopoulos, CG | 1 |
| Baumöhl, J | 1 |
| Schmerber, J | 1 |
| Koumakis, G | 1 |
| Florin, MC | 1 |
| Zacharias, C | 1 |
| Berghmans, T | 1 |
| Mommen, P | 1 |
| Ninane, V | 1 |
| Klastersky, J | 1 |
| Serrone, L | 1 |
| Zeuli, M | 1 |
| Gamucci, T | 1 |
| Nardi, M | 1 |
| Cognetti, F | 1 |
| Montalar, J | 1 |
| Morales, S | 1 |
| Maestu, I | 1 |
| Camps, C | 1 |
| Vadell, C | 1 |
| García, R | 1 |
| Yuste, AL | 1 |
| Torregrosa, D | 1 |
| Segura, A | 1 |
| Christodoulou, C | 1 |
| Klouvas, G | 1 |
| Efstathiou, E | 1 |
| Zervakis, D | 1 |
| Papazachariou, E | 1 |
| Plyta, M | 1 |
| Skarlos, DV | 1 |
| Brun, B | 1 |
| Nasr, E | 1 |
| Randria, G | 1 |
| Feuilhade, F | 1 |
| Gimonet, JF | 1 |
| Le Bourgeois, JP | 1 |
| Itami, S | 1 |
| Ogawa, M | 1 |
| Horikoshi, N | 1 |
| Inoue, K | 1 |
| Mukaiyama, T | 1 |
| Fukutani, H | 1 |
| Tabata, M | 1 |
| Hirano, A | 1 |
| Mizunuma, N | 1 |
| Nakagawa, K | 1 |
| Falkson, G | 1 |
| Chasen, MR | 1 |
| Falkson, HC | 1 |
| Stekar, J | 1 |
| Hilgard, P | 1 |
| Holtei, W | 1 |
| Riemer, U | 1 |
| Chetiyawardana, SD | 1 |
| Joshi, RC | 1 |
| Woodroffe, CM | 1 |
| Westbury, G | 1 |
| Harmer, C | 1 |
| McKinna, A | 1 |
| Fisher, C | 1 |
| Gad-el-Mawla, N | 1 |
| Marti, C | 1 |
| Kroner, T | 1 |
| Remagen, W | 1 |
| Berchtold, W | 1 |
| Cserhati, M | 1 |
| Varini, M | 1 |
| Yoshimoto, J | 1 |
| Akagi, T | 1 |
| Obama, T | 1 |
| Matsumura, Y | 1 |
| Ohkita, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase Ⅱ Single-arm Clinical Trial to Investigate the Efficacy and Safety of Vinorelbine-ifosfamide Regimen as Third-line Treatment in Refractory or Recurrent Extensive Small Cell Lung Cancer Patients[NCT01752517] | 60 participants (Anticipated) | Observational | 2012-12-31 | Recruiting | |||
| Efficacy and Tolerance Adjuvant High-Dose Thiotepa With Peripheral Stem Cell Rescue Associated With Conventional Chemotherapy in Children and Adults With Relapsed Osteosarcoma[NCT00978471] | Phase 2 | 44 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for ifosfamide and Alopecia Cicatrisata
| Article | Year |
|---|---|
[Combination chemotherapy with cis-platinum and ifosfamide for hormone unresponsive prostate cancer].
Topics: Aged; Alopecia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cis | 1998 |
17 trials available for ifosfamide and Alopecia Cicatrisata
| Article | Year |
|---|---|
Doxorubicin and ifosfamide for high-grade sarcoma during pregnancy.
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Sc | 2012 |
[Preliminary result of advanced soft tissue sarcoma treated by MAID regimen].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Fem | 2002 |
Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small- | 2005 |
[Side-effects of polychemotherapy in metastatic testicular neoplasms (author's transl)].
Topics: Adult; Alopecia; Anemia; Bleomycin; Ceruletide; Cisplatin; Constipation; Cyclophosphamide; Drug Ther | 1982 |
Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Double-Blind Met | 1995 |
A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma. The London Gynaecologic Oncology Group.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administrat | 1993 |
Phase II study of high-dose ifosfamide in hepatocellular carcinoma.
Topics: Adult; Aged; Alopecia; Carcinoma, Hepatocellular; Clinical Trials, Phase II as Topic; Female; Humans | 1993 |
Ifosfamide in advanced epidermoid head and neck cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Hea | 1993 |
Ifosfamide seven-day infusion for recurrent and cisplatin refractory ovarian cancer.
Topics: Adult; Aged; Alopecia; Ambulatory Care; Antineoplastic Agents, Alkylating; Female; Hematologic Disea | 1996 |
Phase II trial of paclitaxel and ifosfamide as a salvage treatment in metastatic breast cancer.
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; F | 1997 |
Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer.
Topics: Administration, Oral; Aged; Alopecia; Ambulatory Care; Antineoplastic Agents, Alkylating; Bone Marro | 1997 |
A phase II trial of four courses of preoperative chemotherapy in squamous or anaplastic carcinoma of the oesophagus.
Topics: Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Al | 1998 |
Quality of life (QOL) assessment of MIP (mitomycin, ifosfamide and cisplatin) chemotherapy in advanced non-small cell lung cancers (NSCLC).
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lun | 1998 |
Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-S | 2000 |
A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule.
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemot | 2001 |
Vinorelbine, ifosfamide and cisplatin as first-line treatment in patients with inoperable non-small cell lung cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lun | 2001 |
Effectiveness of the MSC cold cap system in the prevention of chemotherapy-induced alopecia.
Topics: Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined C | 2002 |
14 other studies available for ifosfamide and Alopecia Cicatrisata
| Article | Year |
|---|---|
Comparison of vinorelbine, ifosfamide and cisplatin (NIP) and etoposide and cisplatin (EP) for treatment of advanced combined small cell lung cancer (cSCLC) patients: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2012 |
[Efficacy of DICE (dexamethasone, etoposide, ifosfamide, and cisplatin) regimen on recurrent and refractory non-Hodgkin's lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2006 |
[Chemotherapy of the non-small cell carcinoma of the lung with ifosfamide and cisplatin].
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; C | 1984 |
Toxicity of single- vs. fractionated-dose ifosfamide in non-small cell lung cancer: a multi-center study.
Topics: Alopecia; Brain; Cyclophosphamide; Drug Administration Schedule; Drug Evaluation; Hematuria; Humans; | 1982 |
Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agen | 1996 |
[Pilot study of chemotherapy with mitoxantrone, ifosfamide, 5-fluorouracil in metastatic cancers of the breast. Preliminary study].
Topics: Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cause of Death; Fe | 1991 |
[Combination chemotherapy of ifosfamide, cisplatin and vindesine for non-small cell lung cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lun | 1990 |
Ifosfamide and mesna in combination with other cytostatic drugs in the treatment of patients with advanced cancer.
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small | 1990 |
Protection from ifosfamide-induced alopecia by topical thiols in young rats.
Topics: Administration, Cutaneous; Alopecia; Animals; Female; Ifosfamide; Male; Rats; Rats, Inbred Strains; | 1990 |
Ifosfamide, mitomycin and radiotherapy in non-small-cell lung cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lun | 1989 |
Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Pre | 1986 |
Ifosfamide in advanced pancreatic cancer. A 5-year experience.
Topics: Adult; Alopecia; Anemia; Drug Evaluation; Female; Humans; Ifosfamide; Leukopenia; Male; Mesna; Middl | 1986 |
High-dose ifosfamide in advanced osteosarcoma.
Topics: Alopecia; Bone Marrow; Cyclophosphamide; Humans; Ifosfamide; Nausea; Osteosarcoma; Prospective Studi | 1985 |
[Combination chemotherapy with cisplatin, ifosfamide and adriamycin in patients with advanced transitional cell carcinoma of the urinary tract].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transiti | 1985 |